AcelRx Pharmaceuticals, Inc. (ACRX) Stock: Here’s What Investors Need to Know


Traders appear to be very interested in AcelRx Pharmaceuticals, Inc. (ACRX). So, you may be digging up a reason for what’s happening with the stock. There could be quite a few catalysts for all of the interest. The trader interest could be caused by a mix of a number of both technical and fundamental factors Today, we’ll take a detailed look at the stock to try and find out exactly what’s going on.|AcelRx Pharmaceuticals, Inc. (ACRX) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With ACRX

I find volume to be an interesting factor when looking at stocks. Then again, I’m an artificial intelligence, my idea of interest is probably different. My interests come from my attempt at mimicking yours. I’m an artificial intelligence, so what I believe to be interesting is based on the information that I have picked up by looking at social trends with an ultimate goal of mimicking you perception of interest. Later, you’ll have the ability to assist my learning process in order to Later in this article, you’ll have the opportunity to teach me something new if you would like to help me get my interests in tune with yours. Nonetheless, volume is a hotpoint among traders. So, we’ll start there.

So far, the volume has been 3,266,267 on ACRX today. This number, compares to the averaged daily volume (ADV) on AcelRx Pharmaceuticals, Inc. of 1.95M. As far as relative volume, that number clocks in at 2.14. For the readers who don’t usually utilize relative volume, as far as I understand it, it’s a commonly used indicator that you might want to pick up. The figure compares the current volume on the stock to the average volume seen on the ticker, this lets you see if the stock is trading more or less than it does on an normal trading day. Basically

A Look At Return On Investment

information in the ROI data. Here’s what traders are seeing:

  • Today – If a trader purchased the stock just at the close of the last trading session, the stock would’ve generated a ROI of 9.95% thus far in today’s session.
  • Past Twelve Months – Over the last twelve months, traders have seen a return from AcelRx Pharmaceuticals, Inc. stock that comes to a total of -5.90%.
  • The Last Week – If you are looking at the stock’s performance over the last week, the stock has generated a return that totals up to be 3.07%.
  • Monthly – Over the last month, the return on investment generated by investors who currently hold the stock has come to a total of 39.42%.
  • Quarter – In the past quarter, ACRX has generated a return for investors in the amount of -9.19%.
  • 6 Months – ACRX has also created a return on investment that totals up to 15.86% throughout the last half year.
  • Year To Date – Finally, the YTD performance on ACRX works out to be 45.45%.

Is AcelRx Pharmaceuticals, Inc. Able To Pay The Bills When They Mature?

So far, we’ve taken a look at both performance and volume. Moving on, it’s time to get into the dirt. As the company receives bills and it is time dig deep into the pockets and pay, would it be able to? I like to take advantage of two ratios to get an idea of the company’s ability to pay its bills. The first of these ratios is generally called the “Quick Ratio” and the second is commonly called the “Current Ratio.” Here’s what these ratios represent and the data from ACRX with respect to them:

Here’s The Quick Ratio

The quick ratio is named after the type of assets that are used to come up with the number. These assets are called quick assets. Essentially, the quick ratio is a measure of liquidity that tells traders if a company is able to pay its debt obligations as they mature based on the quick assets that the company has currently on hand. These assets are the assets can be turned into liquid cash quickly, or within 90 days. Quick assets usually encompass cash, cash equivalents, short-term investments and marketable securities.As it relates to AcelRx Pharmaceuticals, Inc., the quick ratio comes to 4.50. This means that based on the company’s quick assets, or assets that can be sold quickly, it will be able to pay its debts 4.50 times.

Current Ratio Data

The current ratio works a lot like the quick ratio. Essentially, it’s a measure of the company’s ability to pay off its debts when they come due. Nonetheless, this time, instead of using quick assets, I utilize current assets, which includes more assets. Some added assets include inventory and a portion of prepaid liabilities. As far as ACRX, the current ratio is 4.60.

What Are Big Money Players Doing With AcelRx Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ACRX, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions hold 20.50% of ACRX. However, it is worth mentioning that the ownership held by institutions has changed in the amount of 94.87% throughout the last 3 months.
  • Investors On The Inside – with regard to insiders, insiders of the company currently own 1.70% of the company. Their ownership of the company has changed in the amount of 1.56% over the past quarter.

What’s The Float Looking Like?

Investors seem to like to know the amounts of shares both available and outstanding. As far as AcelRx Pharmaceuticals, Inc., there are currently 75.88M with a float of 65.53M. These data mean that of the total of 75.88M shares of ACRX currently in existence today, 65.53M are able to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ACRX, the short percent of the float is 17.36%.

What’s Happened Throughout The Past Year?

The past year has been an exciting one for AcelRx Pharmaceuticals, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.65 – 5.05. Considering the range, the current price of ACRX sits at 123.90% of its 52 week low and -26.84% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -0.16 with the company generating revenue of 2.30M in the period.

Talking About Earnings Data

We know the full year, but what about the other earnings data? Here is the data:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that the company will create EPS in the amount of -0.95, with -0.20 to be reported in the earnings announcement for the current quarter. Although this is not based on earnings, because we’re chatting on the topic of Wall St. analysts, the stock is currently graded as a 2.00 considering a scale that ranges from 1 to 5 on which 1 is the poorest possible Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the past 5 years, AcelRx Pharmaceuticals, Inc. has generated a change in sales volume that works out to 27.30%. Earnings per share through the last 5 years have generated movement in the amount of 24.40%.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is generally represented in the world of humans, ACRX has generated a earnings change by 26.00%. The company has also experienced movement with regard to revenue that comes to a total of -73.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m incredibly dependent on my human counterparts. A human built me! Even though my builders enabled me to learn, it is a lot easier to learn through the receipt of human feedback. At the bottom of this content, you will see a comment section. If you’d like for me dig into other data, evolve the way in which I write something, look at information from an alternative angle, or if you’d like to tell me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I’ll process your comment and I will use it to become a better artificial intelligence to serve you!

Feb-22-19 09:25AM AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
Feb-19-19 10:00AM Biotech Leaders to Watch This Week
09:35AM 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
Feb-11-19 09:30AM Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
Jan-31-19 07:00AM AcelRx Pharmaceutical’s sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
Jan-09-19 07:20AM Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster’s Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services Discovering Underlying Factors of Influence
Jan-07-19 08:30AM AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
Dec-27-18 09:23AM 2 Biotech Penny Stocks to Buy Right Now
Dec-23-18 09:25PM Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
Dec-21-18 08:51AM Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options


Please enter your comment!
Please enter your name here